Coverage
-
August 02, 2017
The Third Circuit Wednesday found a June U.S. Supreme Court ruling established investors' claims that Merck & Co. Inc. misrepresented results of a clinical trial of its anti-cholesterol drug Vytorin were filed too late to bring a Securities and Exchange Act case.
3 other articles on this case.
View all »